STAT+: DeepSeek signals China's rising influence in AI — and AI drug development

Is China setting the global standard for AI-driven drug development?

DeepSeek, a relatively unknown AI firm based in Hangzhou, China, shocked the industry last week with claims that its technology could rival the abilities of technologies developed by leading U.S. AI companies — and do so far more economically. The claims ignited debates not just about the implications for AI companies like OpenAI but for the U.S. drug industry, which is increasingly turning to AI in hopes of developing new therapies quicker and more cheaply than ever before.

The cost of training DeepSeek’s large language model was reportedly under $6 million — just a fraction of the billions spent by OpenAI on ChatGPT.

Continue to STAT+ to read the full story…